# A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Source: https://onco.cc/trials/tai-shan6/  
OnCo record `tai-shan6` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing DZD8586 in chronic lymphocytic leukaemia, now recruiting.

## Summary

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) is a phase 3 interventional study registered as NCT07139873, led by Dizal Pharmaceuticals, and recruiting on the registry. Official title: A Phase 3, Open-Label, Randomised, Multicenter Study to Evaluate Anti-tumour Efficacy of DZD8586 Versus Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma. Planned enrolment is 250 participants (estimated). The study started in 2025-09-08 and primary completion is expected in 2029-01. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: TAI-SHAN6
- Tags: ctgov-ingest
- Registry id: NCT07139873
- Phase: 3
- Setting: A Phase 3, Open-Label, Randomized, Multicenter Study to Evaluate Anti-tumor Efficacy of DZD8586 Versus Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Sponsor: Dizal Pharmaceuticals
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT07139873: https://clinicaltrials.gov/study/NCT07139873

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Relapsed or refractory chronic lymphocytic leukaemia](https://onco.cc/cancers/cll-relapsed/)
- drugs: [DZD8586](https://onco.cc/drugs/dzd8586/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)

---
JSON: https://onco.cc/api/v1/entities/tai-shan6.json